Well London Pharma do own the license to Artimist...
I know things have progressed slower than snails pace with Calvin's death and the issues with PP.
But now that London Pharma are in control, and the malaria season is well and truly upon us, and plenty of funding now following the con notes; the company is really set up beautifully now.
We are 2/3 of the way through the trial and IMO it wont be long before the Burkina Faso site can be closed down as it will be completed. I have been following the weather in Ghana closely and since the last trial update 15 days ago it has rained 13 of those days. This thing is moving forward right now.
And then when I look at the chart from the mmv that i posted yesterday it reminds me that there arent many other products at the same stage of development as Artimist.
Throw in the higher absorption rates and the easy administration of the product and I think we are on a winner here and slowly but surely the market will become aware of what EMS has.
Management have presented the results in Boston, been invited by Chevron, have appeared in PDN's annual report, and have also engaged parties to ascertain the appropriate value of the product. All this has happened before the Phase III trial has been completed.
Things will really start ramping up once the results are in and of course when the results are released.
And I come back to the fact that the market cap is under $10m and I am amazed.
I have been frustrated and disappointed like everyone else with the slow progress but when I think about where we are now I am honestly very excited. Things are moving forward on the ground and at the moment that is the most important thing.
EMS Price at posting:
1.6¢ Sentiment: None Disclosure: Held
